These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 17259949)

  • 21. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus vaccines.
    Satyaprakash A; Creed R; Ravanfar P; Mendoza N
    Dermatol Ther; 2009; 22(2):150-7. PubMed ID: 19335726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential mechanisms for HPV vaccine-induced long-term protection.
    Stanley M
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S2-7. PubMed ID: 20494220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?
    Günther OP; Ogilvie G; Naus M; Young E; Patrick DM; Dobson S; Duval B; Noël PA; Marra F; Miller D; Brunham RC; Pourbohloul B
    J Infect Dis; 2008 Jun; 197(12):1653-61. PubMed ID: 18513154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human papillomavirus vaccines in development: if they're successful in clinical trials, how will they be implemented?
    Shaw AR
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S246-8. PubMed ID: 16213009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
    Mahoney MC
    J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cervical cancer prevention in the human papilloma virus vaccine era.
    Ghazal-Aswad S
    Ann N Y Acad Sci; 2008 Sep; 1138():253-6. PubMed ID: 18837904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development.
    Fruscalzo A; Londero AP; Bertozzi S; Lellè RJ
    Minerva Med; 2016 Feb; 107(1):26-38. PubMed ID: 26473283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
    Siddiqui MA; Perry CM
    Drugs; 2006; 66(9):1263-71; discussion 1272-3. PubMed ID: 16827602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT; Castellsagué X; Garland SM
    Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
    Mejia AF; Culp TD; Cladel NM; Balogh KK; Budgeon LR; Buck CB; Christensen ND
    J Virol; 2006 Dec; 80(24):12393-7. PubMed ID: 17005666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
    Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
    Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
    Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical implementation of HPV vaccines in clinical practice.
    Kimmel SR
    J Fam Pract; 2006 Nov; Suppl():18-22. PubMed ID: 17366754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
    Harper DM
    Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Human papillomavirus vaccine. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society. September 2008].
    Abarca V K; Valenzuela B MT; Vergara F R; Luchsinger F V; Muñoz M A; Jiménez de la Jara J; Ripoll M E; O'Ryan G M
    Rev Chilena Infectol; 2008 Dec; 25(6):428-34. PubMed ID: 19194605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chapter 13: Current findings from prophylactic HPV vaccine trials.
    Koutsky LA; Harper DM
    Vaccine; 2006 Aug; 24 Suppl 3():S3/114-21. PubMed ID: 16949998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.